Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Paola Begini"'
Autor:
Filomena Morisco, Alessandro Federico, Massimo Marignani, Flavia L. Lombardo, Valentina Cossiga, Luisa Ranieri, Mario Romeo, Marina Cipullo, Paola Begini, Alessandra Zannella, Tommaso Stroffolini
Publikováno v:
Viruses, Vol 16, Iss 9, p 1439 (2024)
The prediction of liver-related events (LRE) after sustained virological response (SVR) in HCV-advanced chronic liver disease (ACLD) patients is crucial. We aimed to evaluate incidence and risk factors of LRE in HCV-cirrhotic patients after SVR and t
Externí odkaz:
https://doaj.org/article/c50c49c907994ccd9104940767477186
Autor:
Rodolfo Sacco, Vincenzo Messina, Umberto Vespasiani Gentilucci, Luigi Elio Adinolfi, Antonio Ascione, Giorgio Barbarini, Angelo Barlattani, Giuseppe Cariti, Raffaele Cozzolongo, Basilio Fimiani, Ruggiero Francavilla, Caterina Furlan, Giovanni Garrucciu, Vincenzo Iovinella, Luca Rinaldi, Massimo Marignani, Paola Begini, Valeria Pace Palitti, Adriano M Pellicelli, Gaetano Scifo, Antonio Facciorusso, Luca Giacomelli, Aashni Shah, Gaetano Bertino, Serena Perazzo, Giampaolo Bresci, Antonio Izzi
Publikováno v:
Drugs in Context, Vol 9, Pp 1-6 (2020)
Background: The once-daily oral combination of daclatasvir (DCV) and sofosbuvir (SOF), with or without ribavirin (RBV), is effective and well tolerated in patients with hepatitis C virus (HCV). However, further field-practice studies are necessary to
Externí odkaz:
https://doaj.org/article/bc98ae33658645cdb80df67be1e48624
Autor:
Raffaella Lionetti, Paola Piccolo, Ilaria Lenci, Massimo Siciliano, Ubaldo Visco-Comandini, Adriano De Santis, Maurizio Pompili, Martina Milana, Chiara Taibi, Serena Dell’Isola, Marzia Montalbano, Claudio Mastroianni, Paola Begini, Anna Rosa Garbuglia, Mario Angelico, Gianpiero D’Offizi
Publikováno v:
Annals of Hepatology, Vol 18, Iss 3, Pp 434-438 (2019)
Introduction and aim: Cirrhotic patients with hepatitis C virus genotype 3 infection show unsatisfactory outcomes after 12 weeks’ treatment with direct antiviral agents. The National Italian Drug Agency allows 24 weeks of therapy in difficult-to-tr
Externí odkaz:
https://doaj.org/article/643ff804666d4f5a9920a5e944e8f822
Autor:
Paola Begini, Elia Gigante, Giulio Antonelli, Francesco Carbonetti, Elsa Iannicelli, Giulia Anania, Barbara Imperatrice, Adriano Maria Pellicelli, Gianfranco Delle Fave, Massimo Marignani
Publikováno v:
Annals of Hepatology, Vol 16, Iss 1, Pp 107-114 (2017)
Background: Sarcopenia is a complication and independent risk factor for mortality in patients with liver cirrhosis. Aim: To assess the prevalence and influence of sarcopenia on overall survival in a cohort of cirrhotic patients with hepatocellular c
Externí odkaz:
https://doaj.org/article/8ad0a70044e84d138ebe69444233a536
Autor:
Marcello Andrea Tipaldi, Edoardo Ronconi, Elena Lucertini, Miltiadis Krokidis, Marta Zerunian, Tiziano Polidori, Paola Begini, Massimo Marignani, Federica Mazzuca, Damiano Caruso, Michele Rossi, Andrea Laghi
Publikováno v:
Diagnostics, Vol 11, Iss 6, p 956 (2021)
(1) Introduction and Aim: The aim of this study is to investigate the prognostic value, in terms of response and survival, of CT-based radiomics features for patients with HCC undergoing drug-eluting beads transarterial chemoembolization (DEB-TACE).
Externí odkaz:
https://doaj.org/article/77d1c923a40a468fb4c8a7df4ff2164f
Autor:
Marco Canzoni, Massimo Marignani, Maria Laura Sorgi, Paola Begini, Michela Ileen Biondo, Sara Caporuscio, Vincenzo Colonna, Francesca Della Casa, Paola Conigliaro, Cinzia Marrese, Eleonora Celletti, Irene Modesto, Mario Stefano Peragallo, Bruno Laganà, Andrea Picchianti-Diamanti, Roberta Di Rosa, Claudia Ferlito, Simonetta Salemi, Raffaele D’Amelio, Tommaso Stroffolini
Publikováno v:
Microorganisms, Vol 8, Iss 11, p 1792 (2020)
Chronic hepatitis B virus (HBV) infection may be reactivated by immunosuppressive drugs in patients with autoimmune inflammatory rheumatic diseases. This study evaluates HBV serum markers’ prevalence in rheumatic outpatients belonging to Spondyloar
Externí odkaz:
https://doaj.org/article/488f953fd45741108fe7d82eb4f42639
Publikováno v:
Viruses, Vol 11, Iss 9, p 858 (2019)
It is well known that hepatitis B virus reactivation (HBVr) can occur among patients undergoing treatment for hematological malignancies (HM). The evaluation of HBVr risk in patients undergoing immunosuppressive treatments is a multidimensional proce
Externí odkaz:
https://doaj.org/article/98a67c16719f4075b8b0b42b066b69b6
Autor:
Emanuela De Santis, Paola Begini, Alessandra Pecchioli, Elia Gigante, Ilaria Deli, Antonella Tammaro, Salvatore Mariotta, Severino Persechino, Massimo Marignani, Gianfranco Delle Fave
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 1 (2014)
Sarcoidosis is an autoimmune granulomatous disease mainly affecting the respiratory system, which can be associated with cutaneous lesions, cardiac, ocular involvement, and granulomas of liver and spleen. It can develop as an uncommon complication of
Externí odkaz:
https://doaj.org/article/8103c8dedaec4e38877c0d8d36020aa8
Publikováno v:
World Journal of Hepatology
BACKGROUND In December 2019, the coronavirus disease-2019 (COVID-19) emerged and rapidly spread worldwide, becoming a global health threat and having a tremendous impact on the quality of life (QOL) of individuals. AIM To evaluate the awareness of pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ce7b454b5a527e0acc88da0998b7a4b
https://doi.org/10.4254/wjh.v14.i1.274
https://doi.org/10.4254/wjh.v14.i1.274
Autor:
Giampaolo Bresci, Adriano M. Pellicelli, Luigi Elio Adinolfi, Luca Rinaldi, Giovanni Garrucciu, Aashni Shah, Umberto Vespasiani Gentilucci, G. Scifo, Paola Begini, Antonio Facciorusso, Serena Perazzo, A. Barlattani, Giorgio Barbarini, Caterina Furlan, Rodolfo Sacco, Antonio Ascione, Raffaele Cozzolongo, Massimo Marignani, Vincenzo Messina, Giuseppe Cariti, Gaetano Bertino, Basilio Fimiani, Ruggiero Francavilla, Vincenzo Iovinella, Luca Giacomelli, Valeria Pace Palitti, Antonio Izzi
Publikováno v:
Drugs in Context, Vol 9, Pp 1-6 (2020)
Drugs in Context
Drugs in Context
Background The once-daily oral combination of daclatasvir (DCV) and sofosbuvir (SOF), with or without ribavirin (RBV), is effective and well tolerated in patients with hepatitis C virus (HCV). However, further field-practice studies are necessary to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c2261ad1095f36a35659963fda02ddb
https://www.drugsincontext.com/sustained-virological-response-in-patients-with-hcv-treated-with-daclatasvir-sofosbuvir-with-or-without-ribavirin-a-large-field-practice-study
https://www.drugsincontext.com/sustained-virological-response-in-patients-with-hcv-treated-with-daclatasvir-sofosbuvir-with-or-without-ribavirin-a-large-field-practice-study